Faculty Directory
- Name
- Joong Won PARK, M.D., Ph.D.(adjunct professor)
- Faculty Appointment
- Professor, Department of Cancer Control and Population Health, NCC-GCSP
- Area of Expertise
- Internal Medicine/Hepatology
- E-mail
- jwpark@ncc.re.kr
- Work Experience
- Residency in Internal Medicine, Seoul National University Hospital, Seoul (1986-1989)
Obligatory Military Service, Medical Officer(Captain) of Korea Army (1989-1992)
Fellowship, Division of Gastroenterology, Seoul National Univ. Hosp, Seoul (1992-1993)
Instructor, Division of Gastroenterology, Dept. of Internal Medicine, Chung-Ang University (CAU) College of Medicine, Seoul (1993-1995)
Assistant Professor, Division of Gastroenterology, CAU, Seoul (1995-1999)
Visiting Scientist, Center for Basic Research in Digestive Diseases, Mayo Clinic, Rochester, MN, USA (1997-1999)
Associate Professor, Division of Gastroenterology, CAU, Seoul (1999-2002)
Senior Scientist, National Cancer Center, Korea (2002-2008)
Chief, Hepato-biliary-pancreatic cancer branch, Research Institution, NCC, Korea (2006-2009)
Head, Center for Liver Cancer, NCC, Korea (2002-2010)
Head, Translational and Clinical Research I, Research Institution, NCC, Korea (2009-2011)
Principal Scientist, Center for Liver Cancer (Present)
- Educational Background
- M.D., Seoul National University College of Medicine, Seoul, Korea (Feb.1984)
Doctor of Philosophy in Medicine, Seoul National University, Seoul, Korea (Feb. 1996)
- Research Interests
- Dr Park’s research interests are the management of hepatocellular carcinoma, and hepatocarcinogenesis and molecularly targeted therapy.
- International Collaboration
- Chairman of Revision Committee, 2014 KLCSG-NCC, Korea Practice guidelines for the management of HCC (2013-2014)
Member of Guideline Committee, 2013 ILCA practice guideline for the management of intrahepatic cholangiocarcinoma (2012-2013 )
Chairman of Revision Committee, 2011 KASL, Korea Practice guideline for the management of Chronic Hepatitis B (2010-2011)
Chairman of Guideline Committee, 2009 KLCSG-NCC, Korea Practice guidelines for the management of HCC (2008-2009)
Chairman of Scientific Committee, 2008 Seoul Meeting of Asian-Pacific Association for the Study of the Liver (APASL) (2006-2008)
Chairman of Scientific Committee, Korean Association for the Study of The Liver (KASL) (2003-2005)
Director of Scientific Board, Korean Liver Cancer Study Group (KLCSG) (2002-2003)
Treasurer of Korean Society of Gastroenterology (2001-2003)
Member of Korean Medical Association
Member of Korean Society of Gastroenterology
Member of American Gastroenterological Association (AGA)
Member of American Association for the Study of Liver Diseases (AASLD)
Member of Korean Cancer Association
Member of International Liver Cancer Association (ILCA)
- Achievements
-
2022 SCI-E Proton Beam Therapy for Treatment-Naive Hepatocellular Carcinoma and Prognostic Significance of Albumin-Bilirubin (ALBI) Grade: CANCERS. 14(18):4445~ (6.575)
2022 SCI-E Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts: PLOS ONE. 17(3):e0265668~ (3.752)
2022 기타 Sorafenib combined with radiation therapy for advanced hepatocellular carcinoma with portal and hepatic vein invasion extending to the inferior vena cava: a complete response case according to modified RECIST criteri: Journal of Liver Cancer. Online:Published (0)
2022 SCI-E Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma: LIVER CANCER. 11(1):38~47 (11.74)
2021 SCI-E Outcome of Initial Progression during Nivolumab Treatment for Hepatocellular carcinoma:Should We Use iRECIST?: FRONTIERS IN MEDICINE. 8:771887~ (5.093)
2021 SCI-E Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial: LANCET ONCOLOGY. 23(1):77~90 (41.316)
2021 기타 Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment: Journal of Liver Cancer. 21(2):124~138 (0)
2021 SCI-E Associations of Serum Tumor Biomarkers with Integrated Genomic and Clinical Characteristics of Hepatocellular Carcinoma: LIVER CANCER. 10(6):593~605 (11.74)
2021 SCI-E APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy: HEPATOLOGY INTERNATIONAL. 15(5):1031~1048 (6.047)
2021 기타 Characteristics of TP53 and CTNNB1 mutation according to the serum tumor markers in hepatocellular carcinoma: Annals of hepato-biliary-pancreatic surgery. 25 Suppl 1:S38~ (0)
2021 SCI-E Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression: BRITISH JOURNAL OF CANCER. 125(2):200~208 (7.64)
2021 SCI-E Multi-Institutional Retrospective Study of Radiotherapy for Hepatocellular Carcinoma in the Caudate Lobe: FRONTIERS IN ONCOLOGY. 11:646473~ (6.244)
2020 SCI-E Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study: BRITISH JOURNAL OF CANCER. Online:Published (5.791)
2020 SCI-E Synthesis and Cytotoxicity Studies of Bioactive Benzofurans from Lavandula agustifolia and Modified Synthesis of Ailanthoidol, Homoegonol, and Egonol: JOURNAL OF NATURAL PRODUCTS. 83(11):3354~3362 (3.782)
2020 SCI-E Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial: JOURNAL OF HEPATOLOGY. S0168-8278(20):33670-9~ (20.582)
2020 SCI-E Novel Model to Predict HCC Recurrence after Liver Transplantation Obtained Using Deep Learning: a Multicenter Study: CANCERS. 12(10):2791~ (6.126)
2020 SCI-E Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples: NATURE COMMUNICATIONS. 11(1):4748~ (12.121)
2020 SCI-E Sex differences in oncogenic mutational processes: NATURE COMMUNICATIONS. 11(1):4330~ (12.121)
2020 SCI-E Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial: ESMO OPEN. 5(4):e000714~ (5.329)
2020 SCI-E Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma: JOURNAL OF HEPATOLOGY. 73(6):1460~1469 (20.582)
2020 SCI-E Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma: CLINICAL CANCER RESEARCH. 26(18):4795~4804 (10.107)
2020 SCI-E Varices on computed tomography as predictor of survival after hepatic resection in patients with single hepatocellular carcinoma: JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. Online:Published (3.437)
2020 SCI-E Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma: FRONTIERS IN ONCOLOGY. 10:542~ (4.848)
2020 SCI-E Phase I and pharmacokinetic study of the vascular-disrupting agent CKD-516 (NOV120401) in patients with refractory solid tumors: PHARMACOLOGY RESEARCH & PERSPECTIVES. 8(2):e00568~ (2.052)
2020 SCI-E Systematic Review with Meta-Analysis: Low-Level Alcohol Consumption and the Risk of Liver Cancer: GUT AND LIVER. Online:Published (3.141)
2020 SCI-E Pan-cancer analysis of whole genomes: NATURE. 578(7793):82~93 (42.778)
2019 SCI-E First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.: Cancer discovery. 12:1696~1707 (26.37)
2019 SCI-E Comparison of Models for Tumor Recurrence after Liver Transplantation for the Patients with Hepatocellular Carcinoma: A Multicenter Long-Term Follow-Up Study: CANCERS. 11(9):1295~1295 (6.162)
2019 SCI-E 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma(1): Korean J Radiol. 20(7):1042~1113 (3.73)
2019 SCI-E 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma: GUT AND LIVER. 13(3):227~299 (2.968)
2019 SCI-E Efficacy and safety of transarterial chemoembolisation with cone-beam CT in patients with hepatocellular carcinoma within the Milan criteria: a retrospective cohort study: Clinical Radilogy. 74(5):407.e19~407.e28 (2.082)
2019 SCI-E Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma?: CANCERS. 11(2):E230~E230 (6.162)
2019 SCI-E Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis.: Liver Cancer. 4:281~294 (5.944)
2018 SCI Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.: INVESTIGATIONAL NEW DRUGS. 37(3):567~572 (3.502)
2018 SCI-E Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial: Gut. 68(6):1065~1075 (17.016)
2018 SCI-E Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma.: GUT AND LIVER. 13(3):342~348 (2.849)
2018 SCI Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.: JOURNAL OF HEPATOLOGY. 70(4):684~691 (15.04)
2018 SCI-E Incidence and Overall Survival of Biliary Tract Cancers in South Korea from 2006 to 2015: Using the National Health Information Database.: Gut and Liver. 13(1):104~113 (2.849)
2018 SCI Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation: JOURNAL OF KOREAN MEDICAL SCIENCE. 33(45):e286~e286 (1.588)
2018 SCI Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer: CELL REPORTS. 25(5):1304~1317 (8.032)
2018 SCI A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily.: Cell systems. 7(4):422~437 (8.982)
2018 SCI Scoring system for risk stratification of viral reactivation during prophylactic antiviral treatment in Korean patients with hepatitis B undergoing anticancer chemotherapy: A multicenter study.: JOURNAL OF MEDICAL VIROLOGY. 90(10):1593~1603 (1.988)
2018 SCI 11C-acetate and 18F-fluorodeoxyglucose positron emission tomography/computed tomography dual imaging for the prediction of response and prognosis after transarterial chemoembolization.: Medicine. 97(37):e12311~e12311 (2.028)
2018 SCI Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients.: CANCER CELL. 34(2):211~224 (22.844)
2018 SCI Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.: THE NEW ENGLAND JOURNAL OF MEDICINE. 379(1):54~63 (79.26)
2018 기타 Two cases of bronchobiliary fistula: Case report.: Annals of hepato-biliary-pancreatic surgery. 22(2):169~172 (0)
2018 SCI-E Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study.: Liver Cancer. 7(2):148~164 (7.854)
2018 SCI The Immune Landscape of Cancer: Immunity. 48(2):812~830 (19.734)
2018 SCI Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas: CANCER CELL. 33(4):721~735 (22.844)
2018 SCI lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer.: CANCER CELL. 33(4):706~720 (22.844)
2018 SCI A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers: Cancer cell. 33(4):690~705 (22.844)
2018 SCI An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.: CELL. 173(2):400~416 (31.398)
2018 SCI A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples: CELL. 173(2):386~399 (31.398)
2018 SCI Comprehensive Characterization of Cancer Driver Genes and Mutations.: CELL. 173(2):371~385 (31.398)
2018 SCI Pathogenic Germline Variants in 10,389 Adult Cancers: CELL. 173(2):355~370 (31.398)
2018 SCI Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation.: CELL. 173(2):338~354 (31.398)
2018 SCI Oncogenic Signaling Pathways in The Cancer Genome Atlas: CELL. 173(2):305~320 (31.398)
2018 SCI Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics: CELL. 173(2):305~320 (31.398)
2018 SCI Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.: Cell. 173(2):291~304 (31.398)
2018 SCI Genomic and Functional Approaches to Understanding Cancer Aneuploidy: CELL REPORTS. 23(1):313~326 (8.032)
2018 SCI The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.: CELL REPORTS. 23(1):313~326 (8.032)
2018 SCI Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context.: CELL REPORTS. 23(1):297~312 (8.032)
2018 SCI Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types.: CELL REPORTS. 23(2):282~296 (8.032)
2018 SCI Systematic Analysis of Splice-Site-Creating Mutations in Cancer.: CELL REPORTS. 23(1):270~281 (8.032)
2018 SCI Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.: CELL REPORTS. 23(1):239~254 (8.032)
2018 SCI Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.: CELL REPORTS. 23(1):227~238 (8.032)
2018 SCI Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types.: CELL REPORTS. 23(1):213~226 (8.032)
2018 SCI Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.: Cell reports. 23(1):194~212 (8.032)
2018 SCI Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images: CELL REPORTS. 23(1):181~193 (8.032)
2018 SCI Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers.: CELL REPORTS. 23(1):255~269 (8.032)
2018 SCI Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas.: CELL REPORTS. 23(1):172~180 (8.032)
2018 SCI Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.: CELL SYSTEMS. 6(3):282~300 (8.982)
2018 SCI Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines.: CELL SYSTEMS. 6(3):271~281 (8.982)
2018 SCI Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.: Lancet. 391(10126):1163~1173 (53.254)
2018 SCI-E A prospective randomized study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma.: ANNALS OF SURGICAL TREATMENT AND RESEARCH. 94(2):74~82 (1.233)
2017 SCI-E Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma: Oncotarget. 9(3):4034~4043 (5.168)
2017 SCI Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.: The lancet. Gastroenterology & hepatology. 3(1):37~46 (0)
2017 기타 Epidemiology of liver cancer in South Korea.: Clinical and molecular hepatology.. Online:Published (0)
2017 SCI All-treatment array of hepatocellular carcinoma from initial diagnosis to death: observation of cumulative treatments: Journal of Cancer Research and Clinical Oncology. 143(11):2327~2339 (3.503)
2017 SCI-E Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study.: Liver Cancer.. 6(4):313~324 (7.854)
2017 SCI-E Prognostic group stratification and nomogram for predicting overall survival in patients who received radiotherapy for abdominal lymph node metastasis from hepatocellular carcinoma: a multi-institutional retrospective study (KROG 15-02): Oncotarget. 8:94450~94461 (5.168)
2017 SCI-E Current immunotherapeutic strategies in hepatocellular carcinoma: recent advances and future directions.: Therapeutic advances in gastroenterology. 10(10):805~814 (3.648)
2017 SCI-E Noncirrhotic hepatocellular carcinoma: etiology and occult hepatitis B virus infection in a hepatitis B virus-endemic area: Therapeutic advances in gastroenterology. 10(7):529~536 (3.648)
2017 SCI Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma: Cell. 169(7):1327~1341 (30.41)
2017 SCI Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC: Journal of hepatology. 66(6):1166~1172 (12.486)
2016 SCI A Model Predicting Survival of Patients with Recurrent or Progressive Hepatocellular Carcinoma: The MORE Score.: Journal of gastroenterology and hepatology.. 32(3):651~658 (3.322)
2016 SCI Risk-adapted simultaneous integrated boost-proton beam therapy (SIB-PBT) for advanced hepatocellular carcinoma with tumour vascular thrombosis: Radiotherapy and Oncology. 122(1):122~129 (4.817)
2016 SCI-E A New Cell Block Method for Multiple Immunohistochemical Analysis of Circulating Tumor Cells in Patients with Liver Cancer.: Cancer research and treatment. 48(4):1229~1242 (4.245)
2016 SCI-E Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.: Journal of Hepatology. 65(2):289~295 (10.59)
2016 SCI-E Higher Ratio of Serum Alpha-Fetoprotein Could Predict Outcomes in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma and Normal Alanine Aminotransferase.: PLoS One. 11(6):e0157299~e0157299 (3.057)
2016 SCI-E Clinical Characteristics of Patients with Cryptogenic Hepatocellular Carcinoma in a Hepatitis B Virus-Endemic Area: Liver Cancer. 5:21~26 (7.854)
2016 SCI-E Noninvasive Diagnosis of Hepatocellular Carcinoma: Elaboration on Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guidelines Compared with Other Guidelines and Remaining Issues.: Korean J Radiol. 17(1):7~24 (1.592)
2015 SCI Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced epatocellular carcinoma: Annals of Oncology. 26(12):2457~2463 (7.04)
2015 SCI Prognostic indicators for radiotherapy of abdominal lymph node metastases from hepatocellular carcinoma: Strahlentherapie und Onkologie. 191(11):835~844 (2.914)
2015 SCI Normal Liver Sparing by Proton Beam Therapy for Hepatocellular Carcinoma: Comparison with Helical Intensity Modulated Radiotherapy and Volumetric Modulated Arc Therapy: Acta oncologica. 54(10):1827~1832 (2.997)
2015 SCI Downregulation of discoidin domain receptor 2 decreases tumor growth of hepatocellular carcinoma.: Journal of cancer research and clinical oncology. 141(11):1973~1983 (3.081)
2015 SCI-E Korean Version of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma (K-MESIAH).: PLoS One. Online:Published (3.234)
2015 SCI Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study.: Liver international. 35(9):2155~2166 (4.85)
2015 SCI The Role of hepatic resection in the treatment of hepatocellular cancer.: Hepatology. 62(20:440~451 (11.055)
2015 SCI-E SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma: Oncotarget [electronic resource]. 6(18):16449~16460 (6.359)
2015 SCI-E 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma.: Korean journal of radiology. 16(3):465~522 (1.571)
2015 SCI Gα12 gep oncogene deregulation of p53-responsive microRNAs promotes epithelial-mesenchymal transition of hepatocellular carcinoma.: Oncogene. 34(22):2910~2921 (8.459)
2015 SCI Tenofovir Monotherapy versus Tenofovir plus Lamivudine or Telbivudine Combination Therapy in Treatment of Lamivudine-Resistant Chronic Hepatitis B.: Antimicrobial agents and chemotherapy. 59(2):972~978 (4.476)
2015 SCI-E Phase I Dose-Escalation Study of Proton Beam Therapy for Inoperable Hepatocellular Carcinoma.: Cancer research and treatment. 47(1):34~45 (3.318)
2014 기타 Systemic therapy for hepatocellular carcinoma: why do we keep failing?: Hepatic Oncology. 1(4):335~358 (0)
2014 SCI A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma.: Clinical cancer research. 20(23):5976~5985 (8.193)
2014 SCI-E 2014 KLCSG-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma: HCC Diagnostic Algorithm.: Digestive diseases. 32(6):764~777 (1.832)
2014 SCI Simultaneous integrated boost-intensity modulated radiation therapy for inoperable hepatocellular carcinoma: Strahlentherapie und Onkologie. 190(10):882~890 (2.733)
2014 기타 Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma.: Liver Cancer. 3-4:439~50 ()
2014 SCI-E Multicenter validation study of a prognostic index for portal vein tumor thrombosis in hepatocellular carcinoma: Cancer research and treatment. 46(4):348~357 (2.975)
2014 SCI Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.: Strahlentherapie und Onkologie. 190(9):806~814 (2.733)
2014 SCI Long-term outcomes of second treatment after initial transarterial chemoembolization in patients with hepatocellular carcinoma.: Liver international. 34(8):1278~1286 (4.447)
2014 SCI Validation of a model to estimate survival in ambulatory patients with hepatocellular carcinoma: a single-centre cohort study.: Liver international : official journal of the International Association for the Study of the Liver. 34(7):e317~e323 (4.447)
2014 SCI Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma: Journal of hepatology. 60(6):1268~1289 (10.401)
2014 SCI-E microRNA-148a dysregulation discriminates poor prognosis of hepatocellular carcinoma in association with USP4 overexpression.: Oncotarget. 5(9):2792~2806 (6.627)
2014 SCI Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis B virus-endemic area: Journal of Gastroenterology and Hepatology. 29(4):820~829 (3.627)
2014 기타 Clinical Trials of Combined Molecular Targeted Therapy and Locoregional Therapy in Hepatocellular Carcinoma: Past, Present, and Future: Liver cancer. 3(1):9~17 (0)
2014 SCI Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel.: Liver International. 34(2):174~183 (4.447)
2014 SCI Efficacy of argon plasma coagulation in the treatment of radiation-induced hemorrhagic gastroduodenal vascular ectasia: Scandinavian Journal of Gastroenterology. 49(2):238~245 (2.329)
2013 SCI-E Outcomes of Concurrent Chemoradiotherapy versus Chemotherapy Alone for Advanced-stage Unresectable Intrahepatic Cholangiocarcinoma: Radiation Oncology. 21(8):292~292 (2.107)
2013 SCI Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(32):4067~4075 (18.038)
2013 SCI-E Recent advances in systemic chemotherapy of hepatocellular carcinoma: J Korean Med Assoc(JKMA:대한의사협회지). 11:993~1000 (0.183)
2013 SCI Worse Outcome of Sorafenib Therapy Associated with Ascites and Child-Pugh Score in Advanced Hepatocellular Carcinoma1: Journal of Gastroenterology and Hepatology. 28(11):1756~1761 (3.325)
2013 SCI Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(28):3509~3516 (18.038)
2013 SCI Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(28):3517~3524 (18.038)
2013 SCI-E Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer: Radiation Oncology. 8(1):160~160 (2.107)
2013 SCI Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC): Liver international. 33(3):327~337 (3.87)
2013 SCI Transarterial therapies for hepatocellular carcinoma (HCC): A long way towards standardization: Journal of Hepatology. 58(1):195~195 (9.858)
2013 SCI Reply to: “Transarterial therapies for hepatocellular carcinoma (HCC): A long way towards standardization”: Journal of Hepatology. 58(1):195~195 (9.858)
2012 SCI A model to estimate survival in ambulatory patients with hepatocellular carcinoma: Hepatology. 56(2):614~621 (11.665)
2012 SCI Capecitabine plus Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Retrospective Single-Center Study: Chemotherapy. 58(3):225~232 (1.816)
2012 SCI Phase II Study of Concurrent Transarterial Chemoembolization and Sorafenib for Patients with Unresectable Hepatocellular Carcinoma: Journal of hepatology.. 56(6):1336~1342 (9.264)
2012 SCI Multiple Primary Malignant Neoplasms in Pancreatic Cancer Patients: A Single-Center Experience in Korea: Pancreas. 41(4):648~649 (2.386)
2012 SCI Phase II, Open-label Study of Brivanib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma.: Clinical cancer research. 18(7):2090~2098 (7.742)
2012 SCI Dual action of a selective cyclooxygenase-2 inhibitor on vascular endothelial growth factor expression in human hepatocellular carcinoma cells: novel involvement of discoidin domain receptor 2: Journal of cancer research and clinical oncology. 138(1):73~84 (2.558)
2011 SCI Severity and Timing of Progression Predict Refractoriness to Transarterial Chemoembolization in Hepatocellular Carcinoma: J Gastroenterol Hepatol. 27(6):1051~1056 (2.865)
2011 SCI Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia.: Oncology. 2011;81(suppl 1):158~164 (2.538)
2011 SCI Role of Adjuvant Chemoradiotherapy for Resected Extrahepatic Biliary Tract Cancer.: International journal of radiation oncology, biology, physics.. 81:853~859 (4.503)
2011 SCI CA 19-9 Level as Indicator of Early Distant Metastasis and Therapeutic Selection in Resected Pancreatic Cancer: International Journal of Radiation Oncology, Biology, Physics. 81:743~748 (4.503)
2011 SCI Pretreatment Carbohydrate Antigen 19-9 Level Indicates Tumor Response, Early Distant Metastasis, Overall Survival, and Therapeutic Selection in Localized and Unresectable Pancreatic Cancer.: International journal of radiation oncology, biology, physics.. 81:623~630 (4.503)
2011 SCI Survival of Patients with Advanced Hepatocellular Carcinoma: Sorafenib versus Other Treatments.: Journal of Gastroenterology and Hepatology. 26(11):1612~1618 (2.41)
2011 SCI-E Noncontrast chest computed tomography immediately after transarterial chemoembolization in patients with hepatocellular carcinoma : Clinical benefits and effect of radiation reduction on image quality in low-dose scanning: European Journal of Radiology. 80(2):e188~e194 (2.941)
2011 SCI-E Molecularly Targeted Therapies for Hepatocellular Carcinoma : Sorafenib as a Stepping Stone: Digestive Diseases. 29:303~309 (1)
2011 SCI Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma: Journal of gastroenterology and hepatology. 26(7):1201~1206 (2.41)
2011 SCI Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma: Clinical Cancer Research. 17(7):1973~1983 (7.338)
2011 SCI-E Clinical and Virological Responses to Clevudine Therapy of Hepatocelluar Carcinoma Patients with Chronic Hepatitis B: Gut and Liver. 5(1):82~87 (0.219)
2010 SCI-E Liver Cancer Working Group report.: Jpn J Clin Oncol.. 1:19~27 (1.498)
2010 기타 Tumor response in a phase 2 study of first- and second-Line brivanib in hepatocellular carcinoma (HCC): comparison of modified WHO and modified RECIST criteria (초): 대한간학회 , 대한간학회지 | 16권 3s호 94 ~ 94, 총 1 pages. 16:94~94 ()
2010 기타 Comparison of Survival Between Sorafenib and Other Local or Systemic Treatments in Patients with Modified UICC Stage 4 Hepatocellular Carcinoma: a single-center cohort study: 대한간학회 , 대한간학회지 | 16권 3s호 20 ~ 20, 총 1 pages. 16:20~20 ()
2010 기타 An Interim Analysis of a Phase 2 study of the Combination of TACE and Sorafenib in Patients with Unresectable Hepatocellular Carcinoma in National Cancer Center Korea (COTSUN Korea Trial): A Part of Determining Safety: 대한간학회 , 대한간학회지 | 16권 3s호 92 ~ 92, 총 1 pages. 16:92~92 ()
2010 기타 18F-FDG PET-CT-assisted Estimation of Therapeutic Efficacy of Molecular Targeted Agent in Intrahepatic Xenograft Mouse Model of Hepatocellular Carcinoma: 대한간학회 , 대한간학회지 | 16권 3s호 130 ~ 130, 총 1 pages. 16:130~130 ()
2010 기타 Incidence and clinical characteristics of hypertension with sorafenib in patients with advanced hepatocellular carcinoma: 대한간학회 , 대한간학회지 | 16권 3s호 176 ~ 176, 총 1 pages. 16:176~176 ()
2010 기타 Prognostic Factors of Sorafenib Therapy in Patients with Advanced Hepatocellular Carcinoma: 대한간학회 , 대한간학회지 | 16권 3s호 269 ~ 269, 총 1 pages. 16:269~269 ()
2010 기타 Isolated pancreatic metastasis of hepatocellular carcinoma after curative resection: World Journal of Gastrointestinal Oncology. 2(4):209~212 (0)
2009 기타 Practice guidelines for management of hepatocellular carcinoma 2009: The Korean Association for the Study of the Liver , The Korean Journal of Hepato logy. 15(3):391~448 ()
2009 SCI The Societal Burden of HBV-Related Disease: South Korea.: Dig Dis Sci.. 55(3):784~93 (1.838)
2009 SCI Learning curve for living-donor liver transplantation in a fledgling cancer center: Transplant International. 22(12):1164-71:1164~1171 (3.115)
2009 SCI Diagnostic Value of Early-Phase-Enhanced Computed Tomography for the Differentiation of Pulmonary Metastases from Hepatocellular Carcinoma and Primary Lung Cancer.: ACTA RADIOLOGICA. 50:1005~1010 (1.091)
2009 SCI Alpha-fetoprotein and human telomerase reverse transcriptase mRNA levels in peripheral blood of patients with hepatocellular carcinoma: Journal of Cancer Research and Clinical Oncology. 135(8):1091~1098 (2.217)
2009 SCI Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area: Journal of Cancer Research and Clinical Oncology. 135(4):617~625 (2.598)
2009 SCI An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC): Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 27:4577~4578 ()
2008 SCI Does postembolization fever after chemoembolization have prognostic significance for survival in patients with unresectable hepatocellular carcinoma?: Journal of Vascular and Interventional Radiology. 20(2):209~216 (2.217)
2008 SCI Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma: Liver International. 29(2):203~207 (2.559)
2008 SCI A Prospective Evaluation of 18F-FDG and 11C-Acetate PET-CT for Detection of Primary and Metastatic Hepatocellular Carcinoma: The Journal of Nuclear Medicine. Online:Published (5.915)
2008 SCI Influence of lipiodol agent on proton beam range in radiotherapy planning using computed tomography for hepatocellular carcinoma: International Journal of Radiation Oncology Biology Physics. 72:687~694 (4.29)
2008 SCI Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients: Cancer Science. 99(10):2037~2044 (3.165)
2008 기타 폐쇄성 황달로 발현된 간외담관내 간세포암종: 대한간암연구회지. 8:51~54 ()
2008 기타 간세포암종의 표적치료제: 대한간암연구회지. 8:16~17 ()
2008 SCI In reply to dr. Cheng: International Journal of Radiation Oncology Biology Physics. 71(3):961~962 (4.29)
2008 SCI Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma: Cancer Chemotherapy and Pharmacology. Online:Published (2.568)
2007 SCI Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area: Journal of Gastroenterology and Hepatology. 23(3):467~473 (1.785)
2007 기타 Five-year survival analysis of a cohort of hepatocellular carcinoma patients who treated at the National Cancer Center, Korea: Korean J Hepatol. 13(4):530~42 (0)
2007 SCI Accuracy of clinical criteria for the diagnosis of hepatocellular carcinoma without biopsy in a Hepatitis B virus-endemic area: Journal of Cancer Research and Clinical Oncology. 133:937~943 (2.366)
2007 SCI Minimal anhepatic technique for living donor liver transplantation using right liver graft: Liver Transplantation. 13:1611~1613 (4.629)
2007 SCI Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma: International Journal of Radiation Oncology Biology Physics. 69:813~819 (4.463)
2007 SCI Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression.: Hepatology. 46:1401~1408 (10.734)
2007 SCI Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients: Hepatology. 46:446~455 (10.446)
2007 기타 Review: Analysis of Surbibla Rate and Prognostic Factors of Intrahepatic Cholangiocarcinoma: 318 Cases in Single Institute: The Korean Journal of Hepatology. 13:125~128 ()
2007 SCI Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B: Hepatology. 45:1172~1178 (10.734)
2007 SCI Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: Comprehensive study of clinical and immunohistochemical findings in younger Asian patients: Journal of Gastroenterology and Hepatology. 22:491~497 (1.673)
2007 기타 Gastric metastasis of hepatoceluular carcinoma treated by transarterial chemoembolization: a case report: The Korean Journal of Hepatology. 13:91~95 ()
2007 SCI Various liver resections using hanging maneuver by three glisson's pedicles and three hepatic veins: Annals of Surgery. 245:201~205 (7.678)
2007 SCI Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy: International Journal of Radiation Oncology Biology Physics. 67:225~231 (4.556)
2007 기타 A case of hepatectomy for liver metastasis after pancreatoduodenectomy for carcinoma of ampulla of Vater: The Korean Journal of Gastroenterology. 48:434~437 ()
2006 기타 Diagnostic accuracy of 18F-FDG positron emission tomography for evaluation of hepatocellular carcinoma: 대한간학회지. 12:546~552 ()
2006 기타 The adverse effect of indirectly diagnosed portal hypertension in the complicaions and prognosis after hepatic resection of hepatosellular carcinoma: 대한간학회지. 12:553~561 ()
2006 SCI Three-dimensional conformal radiotherapy for unresectable hepatocellular carcinoma patients who were Ineffective to or unsuitable for transcatheter arterial chemoembolization.: American journal of clinical oncology. 29:568~575 (1.615)
2006 SCI Three-Dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable: American Journal of Clinical Oncology. 29:568~575 (1.615)
2006 SCI Geometric Shifting of Porta Hepatis during posthepatectomy radiotherapy for biliary tract cancer: international journal of radiation oncology biology physics. 66:212~216 (4.556)
2006 SCI Isolated caudate lobectomy using the hanging maneuver: Surgery. 139:847~850 (2.566)
2006 SCI Establishment of an indocyanine green test using an automatic chemistry analyzer: CLINICAL CHEMISTRY AND LABORATORY MEDICINE(상위20#이내 학술지 아님). 44:196~198 (1.918)
2006 SCI Postbiopsy arterioportal fistula in patients with hepatocellular carcinoma: clinical significance in transarterial chemoembolization: American Journal of Roentgenology. 186:556~561 (2.209)
2005 기타 Epidemiology of hepatocellular carcinoma in Korea: The Korean Journal of Hepatology. 11:303~310 ()
2005 SCI Cyclooxygenase-2 (COX-2) is directly involved but not decisive in proliferation of human hepatocellular carcinoma cells: Journal of Cancer Research and Clinical Oncology. 0:42850~42859 (2.409)
2005 SCI Risk of Hepatitis B Exacerbation is Low After Transcatheter Arterial Chemoembolization Therapy for Patients with HBV-related Hepatocellular Carcinoma: Report of a Prospective Study.: AMERICAN JOURNAL OF GASTROENTEROLOGY. 100:2194~2200 (4.716)
2005 기타 A Case of Osteoclast-Like Giant Cell Tumor of the Pancreas: Korean Journal of Gastroenterology. 45:441~445 ()
2005 SCI Management of Ascites after Radical Surgery in Gastric Cancer Patients With Liver Cirrhosis and Minimal Hepatic Dysfunction.: WORLD JOURNAL OF SURGERY. 29:653~659 (1.952)
2005 기타 Hepatocellular Carcinoma in Korea: Introduction and Overview.: The Korean Journal of Gastroenterology. 45:217~226 ()
2004 기타 The clinical report of 1,078 cases of hepatocellular carcinomas:National Cancer center experience: Korean Journal of Hepatology. 10:255~297 ()
2004 기타 간세포암종으로 오인된 자발성 파열을 보인 간 혈관근지방종 1예: 대한내과학회지. 67:692~696 ()
2004 기타 심한 비강 출혈로 발현한 비강으로 전이된 간세포암종 1예: Korean Journal of Hepatology. 10:228~232 ()
2004 기타 간세포암종 진료 가이드 라인: 대한간학회지. 10:88~97 (0)
2003 기타 A case of primary leiomyosarcoma of the inferior vena cava treated by surgical resection and reconstruction with synthetic graft replacement: 대한소화기학회지. 42:249~254 ()
2003 기타 간세포암종 진료 가이드라인: 대한간암연구회지. 3:95~106 ()
2003 SCI Plasma levels of D-dimer anad soluble fibrin polymer in patients with hepatocellular carcinoma: a possible predictor of tumor thrombosis: Thromb Res. 109:125~129 (1.446)
2003 SCI Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea.: Journal of hepatology. 38:98~103 (4.974)
2002 기타 간암 조기 발견을 위한 검진의 필요성과 국내외 검진 현황: 대한의사협회지. 45:972~980 ()
2002 기타 진행성 간세포암종 및 전이된 간세포암종의 내과적 치료: 대한간암연구회지. 2:1~7 ()
2002 기타 간암 환자에서 혈청 인터루킨-6 측정의 임상적 유용성: 대한소화기학회지. 39:362~369 ()
2002 기타 비알코올성 지방간염의 자연경과, 진단 및 치료: Medical Postgraduates. 30:124~131 ()
2001 기타 Expression of Mucosal Cyto-Chemokine mRNAs in Patients with Helicobacter pylori Infection: The Korean Journal of Internal Medicine. 16:230~235 ()
2001 기타 한국인에서 분리된 Helicobacter pylori의 항생제 내성률과 Clarithromycin에 대한 내성 기전: 대한내과학회지. 61:587~595 ()
2001 기타 비알코올성 지방간염: 대한소화기학회지. 37:41~52 ()
2001 기타 비알코올성 지방간의 진행: 지질 과산화, 미토콘드리아 장애 및 싸이토카인의 역할: 대한소화기학회지. 38:1~8 ()
2001 기타 Relevance of vacA Genotypes of Helicobacter pylori to cagA and Its Clinical Outcome: The Korean Journal of Internal Medicine. 16:8~14 ()
2000 기타 비알코올성 비장간 환자에서 지방간염의 병리학적 심화도를 예측할 수 있는 임상적 지표들: 대한소화기학회지. 36:782~792 ()
2000 기타 위장과 대장에 발생한 과형성 용종증 1예: 대한소화기내시경학회지. 20:63~67 ()
1999 기타 조기위암에서 진행성 위암으로의 이행성 병변으로서의 고유근층 위암: 대한소화기학회지. 33:183~193 ()
1999 기타 원발성 간세포암 환자에서 간동맥화학색전술 후 발생한 괴사성 간농양 및 담도괴사 1예: 대한간학회지. 5:348~352 ()
1999 SCI Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line: Hepatology. 30:1128~1133 (10.416)
1999 SCI A novel parvovirus isolated from Manchurian chipmunks: VIROLOGY. 253:250~258 (3.363)
1999 SCI Lipopolysaccharide induces cholangiocyte proliferation via and interleukin-6-mediated activation of p44/p42 mitogen-activated protein kinase: Hepatology. 29:1037~1043 (10.416)
1999 기타 Effect of Helicobater pylori infection on antral gasrin and somatostatin cells and on serum gastrin concentrations: 대한내과학회지. 14:15~20 ()
